[1] Picado O,Kwon D,Rojas K,et al. Impact of genomic assays on treatment and outcomes in locally advanced breast cancer[J]. Breast Cancer Res Treat, 2022,94(2):433-447. [2] Sun LN, Zuo CL, Liu XX, et al. Combined photothermal therapy and Lycium barbarum polysaccharide for topicaladministration to improve the efficacy of doxorubicin in the treatment of breast cancer[J]. Pharmaceutics, 2022,14(12):2677. [3] Dong B, Yin XX, Xu H, et al. Application value of modified radical mastectomy in female patients with breast cancer of different molecular types: a prognosis study[J]. Am J Transl Res, 2022,14(4):2490-2496. [4] Yan HX,Gao P,Kong XY,et al. Study on short-term cosmetic effects and quality of life after breast cancer modified radical mastectomy combined with one-stage prosthesis implantation[J]. J Cancer Res Ther, 2022,18(7):1988-1993. [5] Xie XX, Li H, Wang C, et al. Effect of modified radical mastectomy combined with neo-adjuvant chemotherapy on postoperative recurrence rate, negative emotion, and life quality of patients with breast cancer[J]. Am J Transl Res,2022,14(1):460-467. [6] Hachiya K,Masuya M,Kuroda N,et al. Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway[J].Sci Rep, 2021,11(1):19943. [7] Chen S, Zhang YY, Zhang H, et al. Anti-inflammatory effects of NaB and NaPc in Acinetobacter baumannii-stimulated THP-1 cells via TLR-2/NF-κB/ROS/NLRP3 pathway[J]. Acta Pharm, 2022,72(4):615-628. [8] Budke B,Zhong A,Sullivan K, et al. Noncanonical NF-κB factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy[J]. Nucleic Acids Res, 2022,50(11):6251-6263. [9] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范:2015版[J]. 中国癌症杂志, 2015,25(9):92-754. [10] Gervais HW. The ASA classification-solid like a rock in anesthesiology[J]. Anaesthesist, 2017,66(1):3-4. [11] Atoum MF,Hourani HM,Shoter A,et al. TNM staging and classification (familial and nonfamilial) of breast cancer in Jordanian females[J]. India J Cancer, 2010,47(2):194-198. [12] 胡赟宏, 王铮元, 崔嵘嵘, 等. 中性粒细胞/淋巴细胞比值与血小板/淋巴细胞比值对乳腺癌复发转移的预测价值及乳腺癌预后影响因素研究[J]. 中国全科医学, 2016,19(30):3657-3661. [13] 史苇, 蒋琰, 谭黎明, 等. CH3L1、CEA及CA15-3联合检测在乳腺癌诊断中的应用价值[J]. 实用预防医学, 2020,27(8):930-933. [14] Hass HG,Seywald M,Wöckel A, et al. Psychological distress in breast cancer patients during oncological inpatient rehabilitation: incidence, triggering factors and correlation with treatment-induced side effects[J]. Arch Gynecol Obstet, 2023,307(3):919-925. [15] Ahuja D,Kumar V,Gupta N, et al. Comparison of the efficacy of ultrasound guided serratus anterior plane block versus erector spinae plane block for postoperative analgesia after modified radical mastectomy: a randomised controlled trial[J]. Turk J Anaesthesiol Reanim, 2022,50(6):435-442. [16] 程博. 乳腺癌改良根治术患者应用右美托咪定的麻醉效果及其对T淋巴细胞亚群的影响探究[J]. 中国全科医学, 2020,3(S01):143-145. [17] 朱伟, 杨霜, 崔立娟,等. 乳腺癌组织KiSS-1,MMP-2表达水平与老年乳腺癌患者改良根治术预后的关系[J]. 国际检验医学杂志, 2022,43(15):1869-1880. [18] Mulholland BS,Forwood MR,Morrison NA. Monocyte chemoattractant protein-1 (MCP-1/CCL2) drives activation of bone remodelling and skeletal metastasis[J]. Curr Osteoporos Rep, 2019,17(6):538-547. [19] 崔红霞, 许雅娟, 方惠, 等. 脐血S100B、MCP-1、G-CSF在胎膜早破早产儿脑损伤诊断中的价值[J]. 实用预防医学, 2021,28(11):1350-1352. [20] Bellavia D,Costa V,Luca AD,et al. The binomial “inflammation-epigenetics” in breast cancer progression and bone metastasis: IL-1β actions are influenced by TET inhibitor in MCF-7 cell line[J]. Int J Mol Sci, 2022,23(23):15422. [21] 罗洁, 刘世伟, 张蒲蓉, 等. 血清HE4,VEGF,MCP-1及CCL20与乳腺癌患者保乳术后局部复发的关系研究[J]. 现代生物医学进展, 2022,22(14):2778-2783. [22] Khodabandehlou N,Mostafaei S,Etemadi A, et al. Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins[J]. BMC Cancer, 2019,19(1):61. [23] Yeo MK,Kim Y,Lee DH, et al. Cosuppression of NF-κB and AICDA overcomes acquired EGFR-TKI resistance in non-small cell lung cancer[J]. Cancers, 2022,14(12):2940. [24] 贾丽丽, 左东明, 王敬, 等. 老年进展期乳腺癌改良根治术后同侧局部复发的影响因素[J]. 中国老年学杂志, 2021,41(18):3947-3950. [25] 成祥君, 杨璐, 张伟, 等. 不同分子分型乳腺癌血清肿瘤标志物的表达差异与肿瘤复发转移的影响因素[J]. 临床检验杂志, 2019,37(12):893-896. [26] Yi ZB,Yu P,Zhang S,et al. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study[J]. Int J Cancer, 2021,148(3):693-701. [27] Yang YQ, Zhang LG, Tian WJ, et al. Prognosis prediction and risk factors for triple-negative breast cancer patients with brain metastasis: a population-based study[J]. Cancer Med, 2023,12(7):7951-7961.
2024, Vol. 31 
